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Purpose: Irinotecan (CPT-11) and SN-38 – its active metabolite – are alkaloid-derived 
topoisomerase I interactive compounds widely used in various cancer therapy protocols. 
To solve the problems associated with the instability of their lactone ring at physiological pH 
and with the extreme insolubility of SN-38, the development of delivery carriers (eg, liposomes) 
has been considered a subject of unquestionable medical interest. This article focuses on the 
development of an alternative protocol to the classical lipid-film hydration procedures to obtain 
a pharmaceutical formulation for SN-38.
Methods: SN-38-loaded liposomes (SN-38lip) were produced by microemulsification, without 
a prior lipid-film preparation step, and characterized by different methods. Formulation param-
eters were determined by photon correlation spectroscopy, and the SN-38 entrapment efficiency 
was evaluated by absorbance spectroscopy. SN-38lip was obtained as a dry, white powder by 
lyophilization. MTT and LDH assays were conducted to assess the cytotoxic effect of SN-38, 
both in liposomal (SN-38lip) and solubilized form (SN-38sol); flow cytometry was used to 
quantify SN-38 uptake and to analyze cell-cycle phase distribution after drug exposure.
Results: Microfluidic, stable, and controlled sized, negatively charged liposomes, with 
high SN-38 incorporation efficiency into egg yolk phosphatidylcholine (EPC)/L-α-dioleoyl-
phospathidylserine (DOPS) (9:1) vesicles (SN-38lip), were prepared. A lyophilized powder 
of SN-38lip, easily reconstitutable while retaining physicochemical parameters, was finally 
obtained. The efficacy of SN-38lip was assessed by in vitro studies with two tumor cell lines 
(HeLa and Caco-2) and compared with that of SN-38sol. It demonstrated the highest uptake 
of SN-38lip, in accordance with its highest cytotoxicity effect, in comparison with that of 
SN-38sol. In addition, different cell-cycle alterations were induced in both cell lines by the 
liposomal formulation.
Conclusion: The results highlight the potential usefulness of the procured SN-38 liposomal 
formulation and provide the basis for conducting in vivo studies that allow the development of 
alternative strategies for colorectal cancer treatment.
Keywords: microfluidic liposomes, drug delivery, SN-38, cytotoxicity, drug uptake, cell-cycle 
analysis
Introduction
Camptothecins are efficient antineoplastic alkaloid-derived compounds that belong to 
the family of the so-called topoisomerase I (Topo I) interactive compounds.1,2 They 
are natural molecules or semisynthetic analogs, and their solubility properties and 
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antitumor activity are determined by different substituted 
five-ring backbone structure.3 Camptothecins cause cell death 
because of their ability to bind to DNA and Topo I as well as 
to stabilize the complex they both form during replication.4,5 
Topotecan and irinotecan (CPT-11) are two camptothecins 
that have already been approved by the US Food and Drug 
Administration (FDA). Topotecan was approved in 1996 
for the treatment of recurrent ovarian cancer, in 1998 as a 
second-line therapeutic agent in small cell lung cancer, and 
in 2006 for the treatment of advanced, recurrent, and meta-
static cervical cancer.6 CPT-11, in turn, is a first-line drug 
approved for the treatment of a variety of human tumors, 
including colorectal, lung, and gynecological cancers.7 
It has been administered in combination with 5-fluorouracil 
(5-FU) and as a rescue therapy in 5-FU-refractory disease. 
CPT-11 is a water-soluble molecule that can be converted 
by carboxylesterase-catalyzed hydrolysis to its metabolite 
SN-38 and has been reported to have at least 100-fold higher 
activity.8,9 There are, however, certain clinical limitations for 
the use of all of these drugs. These include: 1) spontaneous 
inactivation to a carboxylate form in blood, 2) rapid rever-
sal of the trapped cleavable complex after drug removal, 
requiring prolonged infusions, 3) resistance of cancer cells 
overexpressing membrane transporters, and 4) dose-limiting 
side effects of diarrhea, myelosuppression, neutropenia, and 
an acute cholinergic-like syndrome.10 In the case of SN-38, 
another important drawback is its great insolubility in almost 
all solvents that could be used to properly formulate this drug 
for clinical purposes.
To solve these problems and to optimize the therapeutic 
effectiveness of these drugs, several strategies have been 
examined. Among these, the development of controlled-
delivery carriers, such as liposomes, polymeric nanoparticles, 
or microspheres, provides promising alternatives in the field 
of cancer therapy.11–14
The liposome platform has been extensively studied as 
a tool to encapsulate drugs, and it is considered a subject 
of unquestionable medical interest.15–21 Liposomal devices, 
which have emerged as one of the most studied and useful 
drug delivery systems in the last two decades, provide suit-
able strategies to improve the efficacy of chemotherapeutics 
in cancer treatment. Liposomes can modify the pharmacoki-
netics of the encapsulated drugs, promote their intracellular 
uptake, and allow selective delivery to tumor cells, resulting 
in a decrease in some of the undesirable side effects associ-
ated with chemotherapy and an increase in the maximum 
tolerated dose.11 The US FDA has already approved various 
liposome formulations for clinical use, and many others have 
been tested in clinical trials.22–24
Liposomes offer a wide variety of possibilities to for-
mulate chemically different molecules because of the two 
well-separated environments of their structure. Moreover, 
they are biodegradable, biocompatible, and provide a galenic 
form endowed with drug-sustained-release abilities. The 
pharmacological efficacy of any liposomal formulation is 
dependent on several factors such as physical structure, 
physical stability, and bilayer dynamics. All of these factors 
can be controlled by parameters related to liposome formula-
tion, including lipid composition, preparation method, and 
specific labeling with recognizing molecules. In addition, 
the partition coefficients of the drug molecules in a biphasic 
organic/aqueous system and the interactions that they can 
establish with the lipid components of the liposomal bilayer 
influence the delivery of the encapsulated drugs and the 
stability of the liposomal formulation.25
Recent innovations and developments in nanotechnologies 
have encouraged new research programs to engineer nanotech-
nology products for therapeutic applications, have enabled the 
development and marketing of new bioactive macromolecules 
that require a precise intracellular location for biological 
activity and have revolutionized the form of administering 
medicines.23,26,27 Moreover, smart chemistry has recently 
emerged in developing stimuli-responsive nanocarriers that 
change their structures, composition, or conformations in 
response to external or internal physical or biochemical stimuli, 
which leads to the release of the encapsulated drug.28
The development of sustained-release nanodevices, with 
encapsulated products, is especially useful in the case of 
camptothecins.29,30 There are two main advantages of using 
liposomes for the delivery of these drugs: the protection 
of the liposomal form against hydrolysis of the lactone to 
the inactive carboxylate form and the possibility of solu-
bilizing molecules that are as insoluble as SN-38, whose 
great hydrophobicity limits its application. Until recently, 
CPT-11 – as acidic solution (Camptosar®, Pfizer, USA) – was 
the only form approved for indirect administration of SN-38. 
In October 2015, the US FDA approved an encapsulated form 
of CPT-11 (previously known as MM-398) – the prodrug of 
SN-38 – in liposomes (Onivyde, Merrimack Pharmaceuticals, 
Inc).31 Although it was demonstrated by in vitro experi-
ments that CPT-11 could be converted into SN-38 in intact 
liposomes after their incubation with carboxylesterase,32 
it was also established that only a small fraction of the 
prodrug generates the active metabolite.33 At present, both 
CPT-11 and SN-38 liposomal formulations are being tested 
in clinical trials.19
Sadzuka et al34 reported a comparative study of the 
application of different procedures to incorporate SN-38 into 
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liposomes. The classic protocol – the Bangham method35 – 
showed an encapsulation efficiency of only 5.6%, which 
could be increased up to 20.3% by the application of a 
modified remote-loading method, and up to 53.0% by using 
a novel film-loading method. The poor solubility of SN-38 
would explain the very low encapsulation efficiency achieved 
when conventional methods, involving a hydration step of 
a lipid film, were used. Bala et al33 published a review in 
which some interesting considerations with regard to the 
preparation of nanomedicines for the delivery of SN-38 were 
made. Nevertheless, all approaches to incorporate this drug 
in liposomes are variations of the classic procedure based on 
the hydration of a lipid film.
Improving the formulation of SN-38 is, therefore, an 
interesting approach from a biomedical point of view, given 
its great antitumor activity. Microfluidic techniques con-
stitute an efficacious alternative strategy for liposome pro-
duction. They provide a simple, automatized, continuous 
process that makes possible the scaling of the process for 
the manufacture of large volumes of liposomal suspen-
sions. In addition, microfluidic devices allow an accurate 
control of the physical characteristics of liposome vesicles 
by establishing the most appropriate flow conditions in the 
microfluidic channels, without further processing steps as 
in film hydration methods.36–38 Thus, the pressure, flow rate, 
and number of cycles of circulation of the lipid and drug 
dispersion through the system are key parameters for the 
standardization and optimization of the preparation protocol. 
Furthermore, it has been reported that microfluidic proce-
dures enhance the loading efficiency of both water-soluble 
and hydrophobic drugs.36
This article describes the development and characteriza-
tion of a liposomal-based medicine for SN-38 that constitutes 
a simpler – as well as effective drug-loading – alternative 
than that provided by other published methods. The uptake 
of the liposomal drug by cells and their cytotoxic activity 
has been analyzed and compared with those corresponding 
to the drug solubilized in dimethyl sulfoxide (DMSO) with 
promising results.
Materials and methods
Materials
L-α-distearoyl-phosphatidylcholine (DSPC), egg yolk 
phosphatidylcholine (EPC), soy bean lipid extract (SLE), 
L-α-dioleoyl-phosphatidylserine (DOPS), and choles-
terol (CHOL) were purchased from Avanti Polar Lipids 
(Birmingham, AL, USA). SN-38 was from Tocris Bioscience 
(Bristol, UK). All the organic solvents (Panreac, Montcada y 
Reixac, Barcelona, Spain) were distilled before use. Milli-Q 
water (resistivity 18 MΩ⋅cm; Millipore, Bedford, MA, USA) 
was used. All other chemicals and solvents were of analytical 
grade. Dulbecco’s Modified Eagle’s Medium (DMEM) with 
4.5 g glucose/L, fetal calf serum, L-glutamine, and penicillin–
streptomycin solutions were provided by Biological Indus-
tries (Crowell, CT, USA). Sterile Dulbecco’s phosphate 
buffered saline (PBS), DMSO, 3-[4,5-dimethylthiazol-2-yl] 
2,5-diphenyltetrazolium bromide (MTT), Trypan blue, 
toluidine blue, and Hoechst-33258 (H-33258) were from 
Sigma-Aldrich Chemical Co. (St Louis, MO, USA). The 
CytoScan-Fluoro Assay Kit was provided by G-Biosciences 
(St Louis, MO, USA). Sterilized plastic material was pur-
chased from Corning Incorporated (Corning, NY, USA).
Preparation and characterization of 
sN-38-loaded liposomes
Liposomes were prepared by an initial dispersion of the 
lipids/SN-38 mixture in the preparation buffer with a high-
performance IKA Ultra-Turrax® homogenizer (T25 Digital, 
IKA-Werke GmbH & Co. KG). DSPC, DPPC, DOPS, 
CHOL, SLE, and EPC were used and mixed in binary and 
ternary combinations, at different molar ratios, without prepa-
ration of the standard lipid films. Dry lipids and SN-38 were 
weighted in the same glass recipient, and the proper volume 
of 10 mM, pH 4.4, lactate buffer was added to obtain a lipid 
concentration of 10 mg/mL. After a brief bath sonication, 
intermediate unilamellar liposomes (IUVs) were obtained by 
processing lipids/SN-38 aqueous buffered dispersions with 
a high-pressure Microfluidic device (Avestin M-110EH-30 
Microfluidizer® Processor or Emulsiflex C3). The lipids/
SN-38 suspension was injected into the central channel of the 
Microfluidizer and processed by circulating the suspension 
ten times through the circuit at a pressure of 15,000 psi and 
a flow rate of 50 mL/min. The protocol was standardized, 
and the reproducibility of the different batches obtained was 
analyzed. A white liposomal dry powder was finally obtained 
by lyophilization using trehalose as the cryoprotectant. Two 
milliliters of liposomal suspension were placed in 4-mL 
glass vials and frozen at −80°C (liquid nitrogen) over 3–5 h. 
Vials were subsequently dried for 24 h at −55°C and 0.04 
mbar (Freeze Dryer Alpha 1–2/LD, Martin Christ GmbH, 
Osterode, Germany).
Liposomes – both in suspension and lyophilized forms – 
were visualized by transmission electron microscopy (TEM) 
and scanning electron microscopy (SEM) and systematically 
characterized by measuring particle size and surface charge 
(photon correlation spectroscopy [PCS]) and by quantifica-
tion of the drug loaded into vesicles (absorbance spectros-
copy). Drug encapsulation efficiency (DEE, %), drug bulk 
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concentration, and drug-loading efficiency (mg SN-38/mmol 
lipid) were obtained from the difference between total and 
non-entrapped SN-38. Lipid quantity was measured accord-
ing to Stewart’s method.39
cell cultures and treatments
Experiments were conducted on the tumor epithelial cell 
line HeLa (from cervix adenocarcinoma, ATCC CCL-2) 
and on human Caco-2 colon adenocarcinoma cells (ATCC 
HTB-37) – two well-established models for in vitro testing 
of the efficacy of anticancer drugs.40,41 Cells were grown in 
DMEM supplemented with penicillin, streptomycin, non-
essential amino acids, and fetal bovine serum (FBS). Cell 
cultures were carried out in a humidified sterile atmosphere 
(95% air, 5% CO
2
), at 37°C, in a Nuaire NU-4750 incubator 
(Plymouth, MN, USA). Cells were incubated with different 
concentrations of SN-38 – trapped in liposomes (SN-38lip) 
or solubilized in DMSO (SN-38sol) – for different dura-
tions before measuring the parameters corresponding to 
each assay.
cell survival assessment
Thiazolyl blue (MTT, Sigma) reduction42 was used for the 
assessment of cell survival. Production of MTT formazan 
precipitates, dissolved in 100 µL DMSO per well, was mea-
sured as absorbance at 540 nm in a Synergy H1 microplate 
spectrofluorimeter (BioTek Instruments, Inc., Winooski, 
VT, USA). Cell survival was expressed as the percentage of 
absorption of treated cells in comparison with that of control 
cells (100% survival). The results presented were the mean 
value and SD from at least six independent experiments.
SN-38 uptake by flow cytometry
Flow cytometry was used to quantify the uptake of SN-38 
by HeLa and Caco-2 cells. Cells were treated with 10 µM 
SN-38sol or SN-38lip for up to 48 h. SN-38 fluorescence 
was quickly measured within the cell population (after 
debris exclusion) with a Gallios multicolor flow cytometer 
instrument (Beckman Coulter, Inc, Fullerton, CA, USA). 
Permeabilized (death) cells incorporating propidium iodide 
(PI) were excluded and the uptake was measured according 
to the blue fluorescence (λ
exc
=405 nm, λ
em
=450 nm).
cell-cycle analysis
HeLa and Caco-2 cell-cycle distribution was analyzed by 
flow cytometry after staining the cells to label cellular DNA 
content with PI.43 Flasks of controls and 10 µM SN-38lip-
treated cells were trypsinized (harvesting also detached cells) 
and centrifuged at 1,200 rpm for 5 min for pelleting after 
prior fixing with cold 70% ethanol solution (15 min). After 
centrifugation, the pellet was resuspended in 1 mL fresh PBS 
with 50 µL of a 100 µg/mL solution of RNase and incubated 
for 30 min at 37°C. Immediately prior to measurement, DNA 
was stained by adding 25 µL of 1 mg/mL PI solution. All 
reagents were from Sigma. Measurements were undertaken 
with an Epics XL flow cytometer (Beckman Coulter, Brea, 
CA, USA) with an argon laser line at 488 nm and comple-
mented with the appropriate filters. Cell fractions in Sub-G1, 
G0/G1, S, G2/M, and .4C phases were quantified in histo-
grams with Summit software. Identification of apoptotic cells 
(Sub-G1 region) was achieved by determination of hypoploid 
cell populations. Moreover, polyploid cells were identified in 
the .4C region. For each experiment, a minimum of 20,000 
events were analyzed.
Necrosis analysis
The possible contribution of necrosis to general cell death 
was analyzed by measuring the activity of LDH, released 
into the culture medium of necrotic cells after rupture of the 
plasma membrane44 by using a fluorometric kit (CytoScan-
Fluoro Assay Kit).45 Fluorescence was measured (λ
exc
 560 nm, 
λ
em
 590 nm) after shaking the plates for 15 s in a Synergy 
H1 microplate spectrofluorimeter (BioTek Instruments, Inc., 
Winooski, VT, USA). The percentage of cytotoxicity was 
calculated by using the average fluorescence values from 
experimental, maximum LDH release, and culture medium 
background.
statistical analysis
All data are presented as the mean ± SD from separate 
samples that were analyzed. The statistical significance 
of differences was evaluated by using a Student’s paired 
t-test, where necessary. Data with P,0.05 was considered 
significant (significance levels are indicated in the figure 
legends).
A more detailed version of the other Methods employed 
in this study is given in Supplementary materials.
Results and discussion
Formulation and characterization of 
sN-38-loaded liposomes
Liposome formulations were prepared from DSPC/DOPS/
CHOL (DOC) and EPC/DOPS mixtures, at the appropriate 
molar ratios, and from the natural extracts SLE and EPC. 
The great hydrophobicity of SN-38 imposes substantial 
restrictions on using standard lipid film hydration-based 
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procedures: the solubility characteristics of this molecule, 
as inferred by its partition coefficient,25 must be considered 
when designing a liposomal carrier for its delivery as they 
influence the mechanical properties of lipid bilayers. On the 
other hand, the dynamic properties of the bilayer could 
greatly hinder or facilitate the incorporation of hydropho-
bic molecules such as SN-38. Although carriers with rigid 
bilayers have evident advantages such as low permeability 
and stability in vivo,46 they suffer from considerable restric-
tions in terms of achieving useful pharmaceutical formula-
tions with drug concentrations according to therapeutic 
doses. In contrast, fluid bilayers more easily accommodate 
hydrophobic molecules inside their hydrophobic core. The 
design of the liposomal formulation for SN-38 has taken the 
above considerations into account.
There are some references in the literature about the 
procurement of suitable liposomal devices to encapsulate 
CPT-11 – the prodrug of SN-38. However, despite belong-
ing to the same family of drugs, they have different struc-
tural features that will determine the overall characteristics 
of the carrier synthesis.47,48 Thus, each drug has specific 
requirements to be efficiently and stably encapsulated into 
liposomes. Among these, the lipid composition and the 
manufacturing process – which determine the size, surface 
charge, and bilayer fluidity – are decisive factors for the 
success of the final formulation. Moreover, the efficiency of 
drug loading will depend on its encapsulation in the aqueous 
core, its incorporation into the liposomal bilayer, or its parti-
tion between these two phases. In this way, SN-38 can be 
inserted within the hydrophobic core of a mixed lipid bilayer, 
without disturbing its structure or affecting the stability of 
the formulated liposomes.25
Taking into account the decisive influence of lipid com-
position in the characteristics of liposome populations, we 
have considered different options for the design of liposomal 
formulations. SN-38-loaded liposomes were first prepared 
from a natural SLE. The lipid concentration of the liposomal 
suspensions was fixed at 10 mg/mL. In addition, the influence 
of the lipid/SN-38 molar ratio on the physical properties and 
encapsulation efficiency of liposomes was analyzed. Further, 
it was considered whether the DSPC/DOPS/CHOL lipid mix-
ture used to encapsulate CPT-11 was capable of efficiently 
incorporating its metabolite, SN-38. Alternatively, other 
compositions were assessed: the criterion to select them was 
to obtain liposomes with more fluid bilayers than those given 
by the DSPC/DOPS/CHOL solid mixture and in the results 
of the studies on molecular interactions between this camp-
tothecin and the abovementioned phospholipids. Thus, an 
EPC extract and the binary composition EPC/DOPS were 
also assayed. The results are given in Table 1.
Otherwise, a profound amendment of the methods 
described to date has been made to solve the problems asso-
ciated with the insolubility of SN-38 and in thinking about 
the design of an alternative protocol to obtain an improved 
liposomal formulation for this drug. After discarding methods 
based on the preparation and hydration of lipid films, 
assayed with modest results, we have considered alternative 
procedures such as microfluidic techniques. This method 
has proved useful to procure a controlled-size liposome 
population.36,37 In recent reviews, Garg et al49 and Carugo 
et al50 have emphasized the advantages of applying micro-
fluidic procedures to liposome production as they provide 
improved drug-loading efficiencies, have better binding of 
targeting agents to desired carriers, and ensure reproducible 
manufacturing and uniform scaling.
Liposomes were thus prepared by processing lipid/
SN-38 aqueous buffered dispersions with a high-pressure 
Microfluidic device (Avestin M-110EH-30 Microfluidizer® 
Processor). First, the appropriate amounts of dry powder 
lipids and SN-38 were weighed and dispersed in 10 mM 
lactate (pH 4.4) buffer with a T 25 digital ULTRA-TURRAX® 
dispersing device (IKA, Staufen, Germany). Liposome 
suspensions were stored at 4°C, in the dark, and systemati-
cally characterized by different methods.
It was observed that the lipid/drug molar ratio strongly 
influenced the size and the amount of SN-38 inside vesicles, 
whereas the entrapment efficiency was not affected. The 
results showed that the size of liposomes increased as the 
molar ratio of SN-38 in the lipid/drug mixture increased. 
By considering the PCS data (size analysis) obtained for 
SLE liposomes, the molar ratio selected as the most suit-
able for liposome formulation was 20:1. With this ratio, the 
mean hydrodynamic diameter of the EPC and EPC/DOPS 
liposomes was approximately 150 nm, in the suitable range 
for the biomedical applications for which they are designed, 
whereas the SLE and DOC vesicles were too large. Moreover, 
the results indicate that the efficacy of SN-38 incorpora-
tion into liposomes was always greater than 95% for fresh 
preparations, irrespective of the lipid mixture and the lipid/
drug molar ratio used in the formulation. Obviously, the 
drug bulk concentration in the liposomal/buffer suspension 
was higher for the highest SN-38 molar ratio in the lipid/
drug mixture, ranging from 3.31×10−4 to 17.7×10−4 M. This 
represents an improvement over other liposome formula-
tions reported for SN-38 that were based on film hydration 
procedures.34 However, these results – together with the 
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consideration of the stability of the liposomes suspension 
for all the assayed lipid combinations (see below) and the 
results of previously published biophysical data on interfacial 
interactions of CPT-11 and SN-38 with membrane mimetic 
models using monolayer techniques and differential scanning 
calorimetry25 – argue in favor of the choice of the binary 
EPC/DOPS phospholipid mixture to obtain the most suitable 
formulation for SN-38. The most remarkable aspect of the 
procedure we developed is its simplicity, without the need 
of further processing steps as in film hydration methods, and 
the possibility of formulating within liposomes a molecule as 
insoluble and unstable at physiological pH (due to its lactone 
ring) as SN-38. In addition, the established protocol provides 
vesicles with reproducible physical characteristics in terms 
of particle size, zeta potential values, ability to incorporate 
SN-38 camptothecin, and cytotoxic activity on the cancer cell 
lines analyzed, in the different batches obtained.
If this protocol is compared with others published in 
the literature, the advantages are obvious. Water-soluble 
camptothecins are usually encapsulated into liposomes by 
active loading methods using citrate to create pH gradients, 
with trapping agents to form intraliposomal drug–polyanion 
complexes, ammonium sulfate gradients, or divalent cation/
ionophores. It is more difficult to work with hydrophobic 
molecules and, in many cases, the incorporation processes 
in liposomes are less effective. The restrictions imposed by 
their low solubility in aqueous media make it difficult to use 
methods that are based on the preparation of dry lipid films. 
Zhang et al51 published an alternative procedure to derive 
a liposomal SN-38 formulation that takes advantage of the 
fact that the solubility of this drug increases significantly at 
alkaline pH. However, the method involves undertaking the 
preparation at basic pH (≈10.0) and returning the lyophilized 
sample to an acidic pH (,3.0) during the resuspension 
procedure. All of these alternatives are multistage, highly 
time-consuming procedures that need additional products 
whose effect should be taken into account when evaluating 
the activity of the drug.
Physical stability of sN-38lip suspensions
During storage, SN-38lip vesicles could aggregate and 
precipitate, with consequent changes in their mean size 
and optical density (OD). These changes can be used to 
monitor their physical stability. The stability of the IUV 
suspensions and lyophilized powders was monitored by 
periodic determination of the drug and lipid content in lipo-
somes, the average size and polydispersity of the vesicles, 
and by turbidimetric analysis (absorbance spectroscopy). 
Samples were kept in the dark at 4°C during successive mea-
surements. Firstly, the analysis was carried out during 168 h 
by measuring the OD of the different liposome suspensions 
at 400 nm. Data (Figure 1A) show that their turbidity did not 
undergo significant changes during storage. Accordingly, it 
was ascertained that the increases in vesicle size were never 
greater than 10%.
To enhance the stability during storage, liposome 
suspensions were lyophilized using 5% trehalose as the 
cryoprotectant. Samples were rehydrated immediately and 
at 24 h and 168 h after lyophilization; then, the particle size 
and polydispersity index, zeta potential, and turbidity were 
measured. As shown in Figure 1B, and in comparison with 
the data in Table 1, there were no significant differences in the 
particle size from before to after lyophilization. Likewise, the 
values of zeta potential and turbidity were almost identical 
before and after the lyophilization process. These results 
show that this methodology is suitable to achieve sufficiently 
stable liposomal formulations.
As a measure of stability, the ability of the different 
liposomal formulations to retain the drug inside the vesicles 
was also assessed, in terms of the evolution of this parameter 
during storage. The results show that EPC/SN-38 and 
EPC/DOPS/SN-38lip exhibit a retention rate of ~95% over 
the time period analyzed (Figure 1C).
The morphology of lyophilized liposomes was character-
ized by TEM, using the technique of negative contrast with 
2% uranyl acetate, and by SEM. Both SEM (Figure 2A) and 
TEM (Figure 2B) micrograph images showed that liposomes 
appeared as rounded and intact vesicles with a size close 
to that determined by PCS. A small population of smaller 
vesicles was also observed by TEM.
Taken together, all of the physicochemical data have 
allowed selection of the best lipid/drug ratio (20:1) and 
bilayer composition (EPC/DOPS, 9:1) to develop the final 
formulation for SN-38. This option was supported by previous 
biophysical studies on lipid/camptothecin interactions.25
In vitro assessment of liposomal sN-38 
cytotoxic activity
The quantification of cell cytotoxicity is used to assess the 
efficacy of new drugs and new pharmaceutical formulations. 
The MTT assay was conducted to determine the effect of 
SN-38lip, in comparison with that of SN-38sol, on the sur-
vival and growth of the cell lines HeLa and Caco-2.
A first series of experiments were carried out with HeLa 
cells to establish the importance of the liposome bilayer 
composition on the cytotoxic effect of the drug. The results 
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are shown in Figure 3A and B. Before the study of cell 
survival in the presence of SN-38 solubilized in DMSO or 
incorporated into liposomes (Figure 3), we confirmed that 
blank liposomes and DMSO did not have any effect on cell 
viability. It can be observed that the cytotoxic effective-
ness of the SN-38lip formulations was, in general, higher 
than that of the drug solubilized in DMSO. The possible 
toxicity of DMSO on HeLa and Caco-2 cells was taken into 
consideration before comparatively analyzing the results of 
the MTT assay. DMSO is widely used to solubilize poorly 
soluble drugs in permeation assays because of its well-known 
effect as a chemical penetration enhancer to deliver active 
molecules through the skin and into the cells.52 However, the 
maximum usable concentration of DMSO in cell cultures has 
not been perfectly established, although the toxicity of this 
amphiphilic solvent has already been evaluated in model 
membranes53 and with different cell culture lines.54,55 The 
general consensus is that concentrations of DMSO below or 
equal to 1% are safe for cells in culture, and that 1% DMSO 
does not cause any toxicity to cells.
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Figure 1 Physical stability of sN-38 liposome preparations.
Notes: (A) Optical density measurements of sN-38 liposome suspensions. The measurements were conducted for each formulation indicated in the x-axis. The grup of bars 
for each formulation corresponds to samples  immediately after preparation, and also 24, 72, and 168 h after preparation, from dark blue to light blue. samples were stored 
at 4°c in the dark. (B) size and (C) sN-38 retention rate during storage of lyophilized sN-38 loaded liposomes. The measurements were undertaken for each formulation 
indicated in the x-axis. The grup of bars for each formulation corresponds to samples after rehydration of freshly lyophilized samples and at 24 and 168 h after storage, 
from dark pink to light pink. The measurements were performed, from left to right, after rehydration of freshly lyophilized samples and 24, and 168 h after storage. Data 
correspond to mean values ± sD of, at least, three different experiments. 
Abbreviations: sle, soy bean lipid extract; sN-38, irinotecan metabolite; DOc, DsPc/DOPs/chOl; DsPc, l-α-distearoyl-phospathidylcholine; DOPs, l-α-dioleoyl-
phospathidylserine; chOl, cholesterol; ePc, egg yolk phosphatidylcholine; Zave, Z-average mean.
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At this stage, it is important to underline that, despite the 
effect of DMSO as a permeation enhancer, the SN-38lip for-
mulation was more effective both in increasing the uptake of 
SN-38 by cells (see below) and to improve its cytotoxic activ-
ity. All of these considerations further highlight the importance 
of using delivery systems for drug administration.
Taking into account the results of the characterization 
of all the liposomal formulations (data in Table 1), together 
with those of MTT assays, to evaluate its potential as SN-38 
carriers (data in Figure 3A and B), we conducted a second 
series of MTT experiments, both with HeLa and Caco-2 cells, 
with the SN-38lip formulation chosen as the more appropri-
ate option in terms of stability and cytotoxic activity. EPC/
DOPS (9:1 molar ratio) liposomes were loaded with SN-38 
at a 20:1 molar ratio and used in these series. Cells were 
incubated with a 10 µM SN-38 concentration, both in its 
liposomal form and solubilized in DMSO, for 24 and 48 h; 
quantification measures were carried out immediately (0 h) 
and at 24 and 48 h after drug removal. In a first series of 
experiments, it was checked that the survival of HeLa and 
Caco-2 cells was not affected after its incubation with the 
amount of blank EPC/DOPS liposomes and DMSO necessary 
to provide a 10 µM SN-38 concentration in the incubation 
medium. The results are given in Figure 4.
To select the 10 µM SN-38 concentration, we considered 
the IC
50
 value that could be approximately estimated from the 
data shown in Figure 2B for the chosen liposome formula-
tion (1 µM for incubation times of ~20 h) and the criterion 
of choosing a drug concentration high enough to induce a 
large cytotoxic effect.
The results show the acute cytotoxicity induced by SN-38 
on both HeLa and Caco-2 cell lines: a dramatic decrease in 
cell survival for SN-38-treated cells in relation to control 
cells was observed, which was that the cytotoxicity of the 
drug increased with the incubation time and was dependent 
on the time elapsed after the end of treatment in both cell 
lines. Moreover, the liposomal SN-38 action was always 
stronger than that observed when the drug was adminis-
tered in DMSO, at all of the assayed conditions, despite the 
effect of this solvent as permeation enhancer. The cytotoxic 
effect was particularly high after 48-h treatment with the 
liposomal formulation (never reached 20% survival), and 
the most pronounced differences between the action of the 
liposomal formulation and that of the molecule solubilized 
in DMSO were observed in the case of Caco-2 cells. The 
results are validated by a statistical significance analysis 
of the differences observed between cell survival in HeLa 
and Caco-2 cells incubated with the same amount of SN-38 
solubilized in DMSO (SN-38sol) or incorporated into lipo-
somes (SN-38lip) for all the experimental conditions assayed. 
These results are not surprising when taking into account 
the many bibliographic references showing that liposome 
formulations are one of the best-known alternatives for 
Table 1 Physicochemical characteristics of sN-38-loaded liposomes and sN-38 entrapment inside vesicles
Sample Physical parameters Liposomal SN-38
Liposome composition Lipid/SN-38 
(molar ratio)
Particle 
sizea (nm)
PDIb Zeta-potentialc
(mV)
[SN-38]d 
(μM)
mg SN-38/
mmol lipide
sle (7.5:1)
(10:1)
(20:1)
(40:1)
355.3±13.2
332.8±19.6
196.2±9.4
119.1±1.9
0.472±0.011
0.525±0.058
0.415±0.033
0.398±0.081
−47.7±8.8
−54.3±10.3
−45.3±16.3
−36.1±8.7
1,770.0±10.2
1,329.0±11.3
652.6±7.6
331.3±8.2
52.2±0.3
39.2±0.3
19.3±2.2
9.8±0.2
DsPc/DOPs/chOl (65:35:30) (20:1) 248.3±9.5 0.368±0.016 −32.1±17.5 713.6±6.2 19.7±1.7
ePc (20:1) 146.3±14.2 0.401±0.120 −12.6±1.5 637.5±8.9 19.1±2.6
ePc/DOPs (9:1) (20:1) 147.2±7.9 0.345±0.072 −31.4±7.4 670.2±5.7 20.3±1.6
Notes: aParticle size measured as Z-average mean. bPolydispersity index. cZeta potential. dBulk sN-38 concentration in the liposome suspension. eDrug-loading efficiency, 
expressed as the amount of sN-38 relative to lipid (w/w). lipid concentration in all the samples was 10 mg/ml. Three independent batches were processed and analyzed for 
physicochemical characterization. The data are the mean ± sD values corresponding to three independent preparations.
Abbreviations: sN-38, irinotecan metabolite; sle, soy bean lipid extract; DsPc, l-α-distearoyl-phosphatidylcholine; DOPs, l-α-dioleoyl-phosphatidylserine; chOl, 
cholesterol; ePc, egg yolk phosphatidylcholine.
Figure 2 seM and TeM images.
Notes: seM (A) and TeM (B) images of a lyophilized preparation of sN-38-loaded 
ePc/DOPs liposomes. The bar is equivalent to 100 nm.
Abbreviations: TeM, transmission electron microscopy; seM, scanning electron 
microscopy; sN-38, irinotecan metabolite; ePc, egg yolk phosphatidylcholine; 
DOPs, l-α-dioleoyl-phosphatidylserine.
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improving the therapeutic index of many drugs. Previously, 
we had already demonstrated that liposomes increase the 
cytotoxic effect of CPT-11 (the prodrug of SN-38) on HeLa 
and Caco-2 cells and that HeLa cells are more sensitive to 
the effect of different photosensitizers when loaded into 
liposomes (uncoated or coated with folate), with regard to 
the effect of these drugs solubilized in the appropriate media 
(buffer or DMSO).48,56,57
evaluation of the uptake of liposomal 
sN-38 by hela and caco-2 cells
The study of the ability of a cell to internalize a drug provides 
useful information in relation with its possible therapeutic 
effect and has been widely investigated in biomedical 
research when designing products for pharmaceutical 
applications. The quantitative analysis of the uptake of 
SN-38 – both free and in the liposomal form – by HeLa and 
Caco-2 cells, was carried out by flow cytometry measuring 
the intrinsic fluorescence of this camptothecin derivative 
under ultraviolet excitation. Cells were incubated with 
10 µM SN-38 incorporated into liposomes (SN-38lip) or 
solubilized in DMSO (SN-38sol) for different times, and their 
fluorescence was quantified with the flow cytometer. The 
results are plotted in Figure 5.
Data showed that the amount of SN-38 within cells was 
dependent on the incubation time and that, in both cell lines, 
the uptake was higher for SN-38lip than for SN-38sol. After 
48-h incubation, HeLa cells internalized 28.4% more SN-38 
in their liposomal form than when solubilized in DMSO, 
whereas for Caco-2 this difference increased slightly to 
32.9%. However, the greatest difference was observed after 
24-h incubation (54.8% and 89.4%, respectively). The uptake 
kinetics are somewhat different for HeLa and Caco-2 cells 
and it was observed that, at a given time, HeLa cells internal-
ized a greater amount of drug than Caco-2 cells, irrespective 
of the SN-38 formulation used (liposomal or solubilized). 
These results agree with those of the MTT analysis and 
account for the highest cytotoxicity of the liposomal form.
In a similar way to what was observed for the cyto-
toxic activity, we had already demonstrated that liposomes 
increase the uptake of CPT-11 (the prodrug of SN-38) by 
HeLa and Caco-2 cells. Furthermore, our studies showed 
different uptake kinetics and different amounts of CPT-11 
in cells depending on the cellular type. However, we do not 
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Figure 3 cytotoxic effect of sN-38 solubilized in dimethyl sulfoxide (DMsO) and encapsulated in liposomes.
Notes: (A) survival (%) of hela cells after treatment with sN-38 encapsulated in sle liposomes at different molar ratios. (B) survival (%) of hela cells after treatment with 
sN-38 encapsulated in liposomes with the compositions indicated, at the same lipid/drug molar ratio (20:1) and in DMsO solution. For (A) and (B), cells were incubated for 
24 h with the drug and survival was evaluated 3, 24, and 48 h after drug removal by the MTT assay. cell survival in the presence of the amount of blank liposomes or DMsO 
in the incubation medium, which would contain the amount of drug to provide all tested sN-38 concentrations, was always between 96% and 98%. Data correspond to mean 
values ± sD of at least three different experiments.
Abbreviations: sle, soy bean lipid extract; sN-38, irinotecan metabolite; DOc, DsPc/DOPs/chOl; DsPc, l-α-distearoyl-phospathidylcholine; DOPs, l-α-dioleoyl-
phosphatidylserine; chOl, cholesterol; ePc, egg yolk phosphatidylcholine.
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have additional data to justify the reasons as to why HeLa 
cells internalize, to a greater extent, both the SN-38lip and 
the SN-38sol formulations, as it happens with CPT-11. 
It seems that the different characteristics of these two cell 
types, HeLa and Caco-2, are responsible for the different 
degrees of internalization. Otherwise, the result is in total 
accordance with the cytotoxicity assessment of SN-38 on 
both tumor cell lines.
cell-cycle distribution
The effect of liposomal SN-38 on cell-cycle phase distribu-
tion, after drug exposure, was evaluated by flow cytometry. 
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Figure 4 assessment of survival of hela and caco-2 cells.
Notes: cells were incubated with 10 µM sN-38, both in liposomal form and in dimethyl sulfoxide (DMsO) solution, for 24 (left panels) and 48 h (right panels). The surviving 
fraction was evaluated 0, 24, and 48 h after drug removal by the MTT assay. cell survival in the presence of the amount of blank liposomes and DMsO, which would contain 
the amount of drug to provide 10 µM sN-38 in the incubation medium, was always between 96% and 98%. Data correspond to mean values ± sD of at least six different 
experiments. P-values ,0.03 (*), 0.008 (**), and 0.0001 (***) were statistically significant.
Abbreviations: sN-38sol, irinotecan metabolite solution in DMsO; sN-38lip, irinotecan metabolite in liposomal form.
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HeLa and Caco-2 cells were treated with the EPC/DOPS/
SN-38 (18:2:1 molar ratio) liposomal formulation for 24 
and 48 h and, in each case, cell-cycle profiles were acquired 
immediately (0 h) and 24 h after the drug treatment and 
removal of detached cells. Those profiles were compared 
with the ones obtained for untreated controls. In all cases, 
the SN-38lip concentration was 10 µM. The images given 
in Figure 6A show that, under the same experimental 
conditions, SN-38lip induces different alterations in the 
cell-cycle profile of HeLa and Caco-2 when compared 
with untreated cells. Similar results were obtained by 
Ramasamy et al58 when SCC-7 and MDA-MB-231 cells 
were treated with different formulations of doxorubicin 
and quercetin.
Figure 6B shows the different response of HeLa and 
Caco-2 cells to SN-38 action – the marked influence of 
introducing post-incubation periods after drug treatment and 
before recording the cycle profile and the dramatic changes 
that occur in HeLa cells after SN-38lip treatment. In this case, 
the most significant changes were the huge increase in the 
number of cells in the Sub-G1 phase and the large decrease 
in the percentage of cells at the G0/G1 sector in the two 
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Figure 5 Uptake of sN-38 by hela and caco-2 cells.
Notes: The internalization of the drug was quantified by flow cytometry. Emission fluorescence at 450 nm was determined after excitation at 405 nm. Data are the mean ± sD from 
three independent experiments. Significance was assessed using a Student’s paired t-test; P-values ,0.02 (*), ,0.06 (**), and ,0.003 (***). Fluorescence profiles are representative 
of the three experiments analyzed. The color of the curves indicate the different incubation times: 0 h (black); 3 h (turquoise blue); 6 h (blue); 24 h (red) and 48 h (lilac).
Abbreviations: sN-38sol, irinotecan metabolite solution in DMsO; sN-38lip, irinotecan metabolite in liposomal form.
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assayed conditions (without and with post-incubation times; 
Figure 6B, left panel).
The effect of the post-incubation time on the cell-cycle 
profile showed notable differences with regard to those 
observed when it was acquired immediately after drug incu-
bation. In this case, the number of cells in the G0/G1 phase 
decreased dramatically again, but the increase of Sub-G1 
percentage was much more moderate. The changes in the S, 
G2/M, and .4C sectors were also rather different: cells in 
the S phase showed sustained levels, whereas the G2/M 
and polyploid cells (.4C) showed progressive increases. 
It should be considered that the percentage of cells in all 
cycle phases at 24 h and 48 h after treatment corresponds to 
the evolution of cells remaining after removing the detached 
ones immediately after incubation (0 h). The visualization 
of the histograms shows the profound changes in HeLa cells 
induced by SN-38lip. Previous studies about the effect of 
CPT-11 – the SN-38 prodrug – on different cell lines have 
shown some contradictory results, from cell-cycle arrest at 
S and G2/M phases to apoptotic responses.59,60
The response of Caco-2 cells to SN-38lip treatment 
was quite different (Figure 6B, right panel). The following 
features were observed: 1) a decrease in the proportion of 
cells at the G0/G1 sector, although more moderate than what 
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Figure 6 Flow cytometry analysis of cell-cycle phase distribution.
Notes: cell-cycle phase distribution was analyzed after incubation with sN-38lip (10 µM) for 24 and 48 h. (A) hela (upper panels) and caco-2 (lower panels) cells. cell-cycle 
profiles were acquired for non-treated cells (control) and immediately (24+0 h, 48+0 h) after treatment and 24 h after drug removal (24+24 h, 48+24 h). For comparative purposes, 
typical profiles that were acquired while maintaining the same scale for total counts (y-axis, from 0 to 1,100) and DNA content (x-axis, from 0 to 256), are shown. (B) Percentage of 
cells in each cell-cycle phase calculated from the histograms. (C) Percentages of detached cells in each phase. For each experiment, a minimum of 20,000 events were analyzed.
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was detected for HeLa cells (from 52.7% for control cells, 
down to ~32.1% for treated cells for the longest incuba-
tion time, without a post-incubation period); 2) a cell-cycle 
arrest at the S phase, for which the peak increased from 
19.5% (control cells) up to 35.2% (48-h-treated cells); 3) an 
almost sustained percentage of G2/M cells, irrespective 
of the incubation time, but which slightly decreased when 
post-incubation time was applied; and 4) a lower percent-
age of cells that evolve both toward the Sub-G1 sector and 
the polyploid section, which was more perceptible at 24 h 
post-incubation. In this case, after removing SN-38 and the 
detached cells, the remaining cells, with the internalized drug, 
evolved as they did before. There are significant differences 
such as the important decrease in the G0/G1 population 
(drops to 15%) and the great increase in the number of cells 
in the S phase (up to 49%).
An additional table in Figure 6C shows the analysis of 
the percentage of cells in all cycle phases calculated from the 
cycle profiles corresponding to HeLa and Caco-2 detached 
cells. As it can be observed, almost all detached HeLa cells 
were in the Sub-G1 phase (apoptotic population), whereas 
the highest percentage of Caco-2 cells were in the S region. 
These results are in accordance with the evolution of both, 
HeLa and Caco-2, attached cells when their cycle profiles 
were analyzed at different times, without or with post-
incubation times.
The cytotoxic activity of a CPT-11 liposomal formulation 
on Caco-2 cells, as well as a deep study about the mechanism 
of the death induced by this camptothecin on HeLa and Hs68 
cells, has been reported in the literature.48,56 However, SN-38 
is considered the active metabolite of CPT-11, and diverse 
references point out the convenience of using it instead of 
its prodrug, because of the limited metabolic transformation 
of the latter in vivo.61 The CPT-11lip formulation produced 
severe alterations in the characteristic diploid DNA histogram 
of untreated Caco-2 cells: as suggested, the changes were 
consistent with the progress of an increasing apoptotic pro-
cess induced by this drug in its liposomal form. In contrast, 
the response of Caco-2 cells to SN-38lip is quite different 
in terms of the cell death mechanism, as commented earlier. 
Without analyzing in depth the features associated with 
apoptotic or necrotic processes, it is clear that the cell-cycle 
profile undergoes different changes than those observed 
after incubation with CPT-11lip. From this result, it could 
be interpreted that the cell cycle is arrested at the S phase 
when incubated with SN-38lip, without significant changes 
in the Sub-G1 region (apoptotic population).
The response of colon cancer cells to CPT-11 in solubi-
lized form has also been published.59,62 In general, the most 
common effects observed are arrests of cell cycle at the 
G2/M phase (and at S, sometimes) together with decreases 
of the G1 population. However, it should be noted that there 
are discrepancies in some aspects of the entire cell-cycle 
profiles presented in the most relevant bibliographic refer-
ences consulted.
Considering previous published results and analyzing the 
corresponding data, some similarities and differences with 
those presented here can be observed.56 Thus, the effect of 
SN-38lip on HeLa cells is somewhat similar to that induced 
by CPT-11lip: essentially, there were substantial increases 
of the Sub-G1 peak, as the change induced by SN-38lip was 
much greater. HeLa cells respond to treatment with CPT-11lip 
mainly with increases of the Sub-G1, G2/M, and .4C peaks, 
suggesting an arrest of the cell cycle at G2/M, besides the 
existence of apoptotic cells after incubation with this formula-
tion. The response of HeLa cells to SN-38lip treatment was 
a strong increase of the peak in the Sub-G1 sector together 
with decreases, from dramatic to more moderate, of the peaks 
at the G0/G1, S, and G2/M regions.
With regard to the results of the analysis of the Caco-2 
cycle profile, the comparison under the same treatment 
conditions with CPT-11lip and SN-38lip of cell percent-
ages in the different phases of the cell cycle shows not only 
noticeable similarities but also significant differences. As it 
happens after CPT-11lip treatment, it could be interpreted 
that the cell cycle is arrested at the S phase when incubated 
with SN-38lip; however, unlike those results, changes in the 
Sub-G1 region are considerably lower than those observed 
after treatment with CPT-11lip.
lactate dehydrogenase leakage assay
Cell death induced by the cytotoxic action of a drug can be 
the result of chemical or physical cytoplasmic membrane 
damage associated with a necrotic membrane disruption 
or an apoptotic-mediated membrane blebbing. There are 
several assays to study these processes. The MTT test and 
the LDH assay are two experimental methods used together 
for measuring the levels and the possible causes of cellular 
cytotoxicity as well as for obtaining reliable information 
about the cell death mechanism.63 The measure of the release 
of intracellular enzymes, such as LDH, through permeabi-
lized plasma membranes has proven to be useful to evaluate 
cellular membrane damage and to verify the results of the 
viability assay (MTT).
The results, plotted in Figure 7, showed that the effect 
of SN-38 – either in liposomal suspension or in DMSO 
solution – depended on both the drug concentration and 
the incubation time, with the one caused by the liposomal 
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formulation being slightly more pronounced. The differences 
between HeLa and Caco-2 cell survival after treatment were 
very small. Cell survival decreased by ~40% for the highest 
SN-38lip concentration and the longest incubation time 
and ~30% when the SN-38sol formulation was used, under 
the same conditions. The consideration of the statistical 
significance of the differences observed shows its validity 
for the highest SN-38 concentrations.
Both MTT and LDH assays showed the cytotoxic effect of 
SN-38lip and SN-38sol, although the degree of survival after 
treatment is extremely different depending on the method 
used to evaluate it. Only 17.9% of Caco-2 and 20.6% of HeLa 
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Figure 7 lDh assay after treatment of hela and caco-2 cells with sN-38.
Notes: hela and caco-2 cells were treated with sN-38lip and sN-38sol formulations. The numbers along the x-axis indicate the sN-38 concentration; 1, 10, and 50 µM. 
lDh release was measured at 24 (left panels) and 48 h (right panels). The columns represent the mean percentage of cell survival calculated from lDh release and the error 
bars (±SD) from three independent experiments. Significance was assessed using a Student’s paired t-test; P-values ,0.05 (*), ,0.03 (**) and ,0.02 (***). The data of lDh 
activity in the culture medium was normalized with the total protein content.
Abbreviations: sN-38sol, irinotecan metabolite solution in DMsO; sN-38lip, irinotecan metabolite in liposomal form.
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cells survived after 48-h incubation with 10 µM SN-38lip, as 
measured by the MTT test, whereas survival values of 77.7% 
and 64.6% were determined under the same conditions for 
Caco-2 and HeLa cells, respectively, by the LDH assay. This 
disagreement could indicate that membrane damage does 
not seem to be the main factor involved in the decrease of 
cell viability.
The results described herein are not sufficient to propose 
a mechanism to justify the pathway by which SN-38 exerts 
its cytotoxic action. It should be noted that the release of 
LDH is considered an early event in necrosis, but a late 
event in apoptosis and in long-term assays of both processes 
could be a confounding factor. Our results were observed 
after an incubation time of 24 h with SN-38lip, when the 
survival of Caco-2 and HeLa cells increased up to values of 
91% and 96.2%, respectively, and when the SN-38sol was 
almost non-cytotoxic, are in accordance with this comment. 
Therefore, more research is needed to draw conclusions about 
the mechanism of the cytotoxic effect of SN-38, and studies 
are currently underway to more precisely establish the action 
mode of SN-38 in its liposomal form.
Conclusion
The development of controlled-delivery, sustained-release 
nanodevices, such as liposomes, is providing promising alter-
native tools in the field of cancer therapy and it is especially 
useful in the case of camptothecins because of their chemical 
characteristics. The present article reports the preparation 
of a new liposomal formulation for SN-38 designed with 
a careful selection of the liposomal lipid components, the 
optimal drug lipid ratio, and the proper methodology, taking 
into account our previous drug–lipid interaction studies. Its 
potential for cancer chemotherapy is determined in vitro 
as a first and necessary step before in vivo assays.64 The 
results obtained have allowed establishment of the follow-
ing considerations: 1) SN-38-loaded liposomes have been 
successfully formulated and obtained by a microfluidic 
protocol which gives stable and well-characterized vesicle 
suspensions. The SN-38lip formulation has been lyophilized 
to provide a readily reconstitutable white liposomal powder 
which maintains its physicochemical properties and drug 
retention ability practically unchanged after resuspension; 
2) SN-38 was better internalized by HeLa and Caco-2 cells 
when formulated in liposomal devices than when solubilized 
in DMSO, despite the effect of this solvent as a permeation 
enhancer; 3) the cytotoxicity of SN-38, both in liposomal 
and solubilized form, has been demonstrated by means 
of two complementary experimental methods – the MTT 
reduction assay and the LDH release test. The improved 
cytotoxic effect of SN-38 when liposomes were used as 
delivery carriers could be directly related with the greater 
internalization of the liposomal form of the drug; 4) the cel-
lular response to SN-38 of HeLa and Caco-2 cells showed 
noticeable differences, being the more significant the huge 
increase in the number of HeLa cells in the Sub-G1 phase, 
that could be related to an apoptotic cell death process, and 
an arrest of the Caco-2 cell cycle in the S phase, which may 
lead to the suppression of cell proliferation. In any case, it 
has been proposed that both actions could constitute a barrier 
for cancer progression.
The results obtained highlight the potential of the devel-
oped formulation and prove the benefits of using liposomes 
in cancer therapy. Furthermore, they underline the need for 
more research to draw conclusions about the exact mecha-
nism by which SN-38 exerts its cytotoxic action, and studies 
to elucidate this are currently underway.
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Supplementary materials
Preparation of sN-38-loaded liposomes
A suspension of multilamellar liposomes (MLVs) was 
first prepared by direct hydration of lipids and SN-38. 
L-α-distearoyl-phosphatidylcholine (DSPC), DPPC, L-α-
dioleoyl-phosphatidylserine (DOPS), cholesterol (CHOL), 
soy bean lipid extract (SLE), and egg yolk phosphatidyl-
choline (EPC) were used and mixed in binary and ternary 
combinations, at different molar ratios, without preparation 
of the standard lipid films. The appropriate amounts of lipids 
and SN-38 were weighed together, and MLVs were formed 
by hydrating the dry powder of lipid/SN-38 mixtures with 
10 mM lactate (pH 4.4) buffer to a final lipid concentration 
of 10–20 mg lipid/mL. The hydration was done with a T 25 
digital ULTRA-TURRAX® dispersing device (IKA, Staufen, 
Germany). MLV dispersions were sonicated for 10 min in 
an ultrasonic bath (Branson, Danbury, CT, USA) above 
the phase-transition temperature (Tm) and processed by a 
high-pressure Microfluidic device (Avestin M-110EH-30 
Microfluidizer® Processor or Emulsiflex C3). The Emulsiflex 
C3 processor is a high-pressure homogenizer designed for 
laboratory-scale production by continuous, high-shear, fluid 
processing, easily scalable up to pilot and/or production vol-
umes with guarantee of repeatability. Liposomes size can be 
controlled by adjusting the fluid flow rates in the microfluidic 
network. Liposomes were stored in the dark at 4°C.
lyophilization process
To enhance stability during storage, liposomes were lyo-
philized using 5% trehalose as the cryoprotectant agent. The 
protocol was established as follows: 2 mL liposomal sus-
pension was placed in 4 mL glass vials and frozen at −80°C 
(liquid nitrogen) for 3–5 h. Vials were subsequently dried for 
24 h at −55°C and 0.04 mbar (Freeze Dryer Alpha 1–2/LD, 
Martin Christ GmbH, Germany). Lyophilized liposomes 
were rehydrated immediately before the experiments by 
adding 2 mL of 10 mM lactate (pH 4.4) buffer. The resulted 
suspension was prewarmed at 45°C for 15 min and vortexed 
for 30 min (alternating 30 s periods of heating/vortexing).
characterization of liposomes
Determination of the lipid content
The lipid amount in liposome suspensions was measured fol-
lowing Stewart’s method.1 Calibration curves for each lipid 
composition (0.01–0.2 mg lipid) were obtained. Chloroform 
and ammonium ferrothiocyanate (1:1, v/v) were added to 
each dried sample. The chloroformic phase, extracted after 
vortexing and centrifugation (2,680×g, 10 min), was used 
to select the absorbance maximum. Measures were carried 
out in a Specord 205 UV/VIS spectrophotometer (Analytical 
Jena AG, Jena, Germany).
Vesicle size and zeta potential
The average particle size, particle size distribution, and 
zeta potential of unilamellar liposomes were determined by 
dynamic light scattering (DLS) and laser Doppler micro-
electrophoresis in a Malvern Zetasizer NANO-ZS device 
(Malvern Instruments Ltd, Malvern, UK) equipped with an 
optic unit containing a 5 mW He-Ne laser (Spectra Physics) 
and an electrophoresis cell. The device was calibrated with 
standard carboxy-modified polystyrene latex samples. 
Measurements were carried out at 25°C and λ
exc
=633 nm, 
using liposomal suspensions containing 0.2 mg lipid/mL of 
10 mM, pH 4.4, lactate buffer. Data were collected with a 
Malvern data channel correlator and the mean hydrodynamic 
diameter was calculated from a cumulative analysis of the 
intensity autocorrelation function.
Transmission electron microscopy
A direct observation of liposomes was carried out by trans-
mission electron microscopy (TEM). Ammonium molybdate 
(2.0%) was used for negative staining to visualize vesicles. 
Liposomal dispersion was placed on a carbon-Formvar-
coated copper grid for 1 min, after which 10 µL negative 
stain was used for 30 s and the excess sample and stain was 
blotted with filter paper. Afterward, the copper grid was 
air-dried for imaging using an electron microscope JEOL 
JEM 1010 100 kv, with CCD Megaview 1 k×1 k (JEOL 
Ltd., Tokyo, Japan).
Entrapment efficiency and SN-38 liposomal content
Total and entrapped SN-38 was systematically quantified 
by UV-vis absorption spectroscopy. A calibration curve for 
SN-38 (1–30 µM) was previously obtained in dimethyl sul-
foxide (DMSO) at λ
max
 (390 nm). Liposome-entrapped SN-38 
was quantified as the difference between the total SN-38 
used to prepare the film and the amount of non-encapsulated 
drug. An aliquot of the liposomal-SN-38 suspension was 
centrifuged using Centricon YM-10 Filter Devices (Millipore 
Corporation, Billerica, MA, USA) to obtain a filtrate con-
taining the non-entrapped drug, without liposomes. The 
concentration of non-entrapped SN-38 was determined by 
comparison with the calibration curve obtained in the same 
conditions. Drug encapsulation efficiency (DEE%) and drug-
loading efficiency (mg SN-38/mmol lipid) were calculated 
as the amount of drug inside liposomes with respect to the 
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Microfluidics preparation of SN-38-loaded liposomes
total amount of drug or lipids added in preparing formula-
tion, respectively.
liposomes stability
To control the stability of the formulations, both before and 
after the lyophilization process, the drug and lipid content 
in liposomes as well as the average size and polydispersity 
of the vesicles were determined. The turbidity of all samples 
was determined by diluting the suspension in 10 mM, pH 4.4 
lactate buffer and measuring the absorbance of the sample 
at 400 nm in a Specord 205 UV/VIS spectrophotometer 
(Analytical Jena AG, Jena, Germany). The size and the drug 
content were determined as described previously.
cell cultures
Experiments were conducted on the tumor epithelial cell 
line HeLa (originated from a cervix adenocarcinoma, ATCC 
CCL-2) and the human Caco-2 colon adenocarcinoma cells 
(ATCC HTB-37). Both of these are well-established models 
for in vitro testing of the efficacy of anticancer drugs.2,3 
Both cell lines were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 50 U/mL penicillin, 
50 µg/mL streptomycin, 1% nonessential amino acids, and 
FBS at a final concentration of 10%. Cell cultures were 
carried out in a humidified sterile atmosphere of 95% air and 
5% CO
2
, at 37°C, in a Nuaire NU-4750 incubator (Plymouth, 
MN, USA). Cells were grown for 72 h and treated when 
cultures were in exponential growth.
In vitro studies of liposomal sN-38 
cytotoxic activity
Cells were incubated with different concentrations of 
SN-38 – either entrapped in liposomes (SN-38lip) or solu-
bilized in DMSO (SN-38sol) – at different times between 
0 and 48 h to assess the cellular uptake of the drugs using flow 
cytometry. For cell survival studies and cell-cycle analysis, 
24 h and 48 h of incubation with post-incubation times of 
up to 48 h were used.
cell survival
HeLa and Caco-2 cells were incubated with concentrations of 
SN-38lip or SN-38sol ranging from 1 to 50 µM for 3, 24, and 
48 h. Thiazolyl blue (MTT, Sigma) reduction4 was used for 
the assessment of cell survival. Briefly, a MTT stock solution 
in PBS (1 mg/mL) was prepared immediately prior to use and 
diluted in complete medium to achieve a final concentration 
of 50 µg/mL (100 µL MTT stock solution to each 2 mL of 
medium). Cells were incubated for 2 h to allow formazan 
crystals to precipitate. Formazan precipitates were dissolved 
in 100 µL DMSO per well and the absorbance was measured 
at 540 nm in a Synergy H1 microplate spectrofluorimeter 
(BioTek Instruments, Inc., Winooski, VT, USA). Cell survival 
was expressed as the percentage of absorption of treated cells 
in comparison with that of control cells (100% survival). The 
results presented were the mean value and SD from at least six 
independent experiments. Another set of experiments with the 
10 µM concentration of SN-38 was conducted with incubation 
times of 24 h or 48 h and post-incubations times up to 48 h.
SN-38 uptake by flow cytometry
Flow cytometry was used to quantify the uptake of SN-38 
by HeLa and Caco-2 cells. Cells cultured on 25 cm2 flasks 
were treated with 10 µM SN-38sol or SN-38lip for up to 
48 h. After incubation, cells were washed twice with PBS, 
in order to remove the drug outside the cells, and cells 
were trypsinized and centrifuged at 1,200 rpm before final 
resuspension in 1 mL PBS. SN-38 fluorescence was quickly 
measured within the cell population (after debris exclusion). 
The analysis was carried out using a Gallios multi-color flow 
cytometer (Beckman Coulter, Inc, Fullerton, CA, USA) 
set up with the three-lasers, ten-colors standard configura-
tion. Excitation was done using a blue (488 nm) laser for 
forward scatter (FS) and side scatter (SS). A gate on cells 
was settled on this dot plot, in order to exclude small debris 
and aggregates. Red fluorescence from propidium iodide 
(PI; 2–4 µg/mL) was collected in a log scale (λ
exc
=488 nm, 
λ
em
=620 nm). Permeabilized (death) cells incorporating PI 
were excluded. Uptake was measured according to the blue 
fluorescence (λ
exc
=405 nm, λ
em
=450 nm). Results were pro-
jected on a 1024-channel histogram, where the percentage 
of positive cells was measured.
cell-cycle analysis
HeLa and Caco-2 cell-cycle distribution was analyzed by flow 
cytometry after staining the cells, to label cellular DNA con-
tent, with PI.5 Flasks of controls and 10 µM SN-38lip-treated 
cells were trypsinized (harvesting also detached cells) and 
centrifuged at 1,200 rpm for 5 min for pelleting before fixing 
with cold 70% ethanol solution (15 min). After centrifuga-
tion, the pellet was resuspended in 1 mL fresh PBS with 50 
µL of a 100 µg/mL solution of RNase and incubated for 30 
min at 37°C. Immediately prior to measurement, DNA was 
stained by adding 25 µL of 1 mg/mL PI solution. All reagents 
were from Sigma. Measurements were carried out with an 
Epics XL flow cytometer (Beckman Coulter, Brea, CA, USA) 
with an argon laser line at 488 nm, and complemented with 
the appropriate filters. Cell fractions in Sub-G1, G0/G1, S, 
G2/M, and .4C phases were quantified in histograms with 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
1.
11
6.
16
8.
89
 o
n 
09
-A
pr
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
 MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
5320
casadó et al
Summit software. Identification of apoptotic cells (Sub-G1 
region) was achieved by determination of hypoploid cell 
populations. Polyploid cells were also identified in the .4C 
region. For each experiment, a minimum of 20,000 events 
were analyzed.
Necrosis analysis
To study the possible contribution of necrosis to the general 
death, we conducted a test to measure the activity of the 
enzyme LDH, which is released into the culture medium of 
necrotic cells following rupture of the plasma membrane.6 For 
this purpose, a fluorometric kit (CytoScan-Fluoro Assay Kit) 
for measuring LDH release was employed according to the 
manufacturer’s instructions (G-Biosciences, St Louis, MO, 
USA).7 Cells were seeded in black 96-well plates and treated 
for 24 h or 48 h with 100 µL culture medium containing 
concentrations ranging from 1 to 50 µM of SN-38 either as 
SN-38lip or SN-38sol. Plates were removed from the incu-
bator and equilibrated to room temperature for 20–30 min. 
In total, 100 µL of the reaction buffer, containing the LDH 
substrates, were added to each well, mixed with the medium, 
and incubated for 10 min at room temperature prior to the 
addition of 50 µL of the stop solution. Fluorescence was 
measured with an excitation at 560 nm and emission at 590 nm 
after shaking the plates for 15 s in a Synergy H1 microplate 
spectrofluorimeter (BioTek Instruments, Inc., Winooski, VT, 
USA). The percentage of cytotoxicity was calculated by using 
the average fluorescence values from experimental, maximum 
LDH release, and culture medium background.
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